GI
SLS icon

GAMMA Investing’s SELLAS Life Sciences SLS Stock Holding History

GAMMA Investing’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.21K Sell
556
-259
-32% -$1.79K ﹤0.01% 3292
2026
Q1 		$3.45K Buy
815
+443
+119% +$1.98K ﹤0.01% 3504
2025
Q4 		$1.4K Buy
+372
New +$723 ﹤0.01% 3703

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GAMMA Investing's SLS Position: Q2 2026 in Review

GAMMA Investing reduced its SELLAS Life Sciences (SLS) stake by 32% in Q2 2026, selling an estimated $1.79K and leaving 556 shares worth $8.21K. The position accounts for ﹤0.01% of the portfolio, ranked #3292.

GAMMA Investing first reported a position in SLS in Q4 2025 and has held it in 3 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • GAMMA Investing held 556 shares of SELLAS Life Sciences worth $8.21K as of Q2 2026.
  • GAMMA Investing sold 259 SELLAS Life Sciences shares in Q2 2026, an estimated $1.79K.
  • SELLAS Life Sciences made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3292 holding.
  • GAMMA Investing first reported a position in SELLAS Life Sciences in Q4 2025 and has held it in 3 quarters since.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.